Letters
Volume 28—2022
Volume 28, Number 5—May 2022
Guillain-Barré Syndrome Associated with COVID-19 Vaccination [PDF - 237 KB - 2 pages]
| EID | Finsterer J, Scorza FA, Scorza CA. Guillain-Barré Syndrome Associated with COVID-19 Vaccination. Emerg Infect Dis. 2022;28(5):1079-1080. https://doi.org/10.3201/eid2805.212145 |
|---|---|
| AMA | Finsterer J, Scorza FA, Scorza CA. Guillain-Barré Syndrome Associated with COVID-19 Vaccination. Emerging Infectious Diseases. 2022;28(5):1079-1080. doi:10.3201/eid2805.212145. |
| APA | Finsterer, J., Scorza, F. A., & Scorza, C. A. (2022). Guillain-Barré Syndrome Associated with COVID-19 Vaccination. Emerging Infectious Diseases, 28(5), 1079-1080. https://doi.org/10.3201/eid2805.212145. |
SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia [PDF - 237 KB - 2 pages]
| EID | Grassia JT, Markwalter CF, O’Meara WP, Taylor SM, Obala AA. SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia. Emerg Infect Dis. 2022;28(5):1080-1081. https://doi.org/10.3201/eid2805.220404 |
|---|---|
| AMA | Grassia JT, Markwalter CF, O’Meara WP, et al. SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia. Emerging Infectious Diseases. 2022;28(5):1080-1081. doi:10.3201/eid2805.220404. |
| APA | Grassia, J. T., Markwalter, C. F., O’Meara, W. P., Taylor, S. M., & Obala, A. A. (2022). SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia. Emerging Infectious Diseases, 28(5), 1080-1081. https://doi.org/10.3201/eid2805.220404. |
Melioidosis in Children, Brazil, 1989–2019 [PDF - 237 KB - 2 pages]
| EID | Behera B, Radhakrishnan A, Mohapatra S, Mishra B. Melioidosis in Children, Brazil, 1989–2019. Emerg Infect Dis. 2022;28(5):1081-1082. https://doi.org/10.3201/eid2805.211473 |
|---|---|
| AMA | Behera B, Radhakrishnan A, Mohapatra S, et al. Melioidosis in Children, Brazil, 1989–2019. Emerging Infectious Diseases. 2022;28(5):1081-1082. doi:10.3201/eid2805.211473. |
| APA | Behera, B., Radhakrishnan, A., Mohapatra, S., & Mishra, B. (2022). Melioidosis in Children, Brazil, 1989–2019. Emerging Infectious Diseases, 28(5), 1081-1082. https://doi.org/10.3201/eid2805.211473. |
Melioidosis in Children, Brazil, 1989–2019 (response) [PDF - 212 KB - 1 page]
| EID | Lima R, Rolim D. Melioidosis in Children, Brazil, 1989–2019 (response). Emerg Infect Dis. 2022;28(5):1081-1082. https://doi.org/10.3201/eid2805.220479 |
|---|---|
| AMA | Lima R, Rolim D. Melioidosis in Children, Brazil, 1989–2019 (response). Emerging Infectious Diseases. 2022;28(5):1081-1082. doi:10.3201/eid2805.220479. |
| APA | Lima, R., & Rolim, D. (2022). Melioidosis in Children, Brazil, 1989–2019 (response). Emerging Infectious Diseases, 28(5), 1081-1082. https://doi.org/10.3201/eid2805.220479. |
High-Dose Convalescent Plasma for Treatment of Severe COVID-19 [PDF - 197 KB - 1 page]
| EID | Focosi D, Casadevall A. High-Dose Convalescent Plasma for Treatment of Severe COVID-19. Emerg Infect Dis. 2022;28(5):1083. https://doi.org/10.3201/eid2805.220191 |
|---|---|
| AMA | Focosi D, Casadevall A. High-Dose Convalescent Plasma for Treatment of Severe COVID-19. Emerging Infectious Diseases. 2022;28(5):1083. doi:10.3201/eid2805.220191. |
| APA | Focosi, D., & Casadevall, A. (2022). High-Dose Convalescent Plasma for Treatment of Severe COVID-19. Emerging Infectious Diseases, 28(5), 1083. https://doi.org/10.3201/eid2805.220191. |
High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response) [PDF - 206 KB - 2 pages]
| EID | De Santis GC, Calado RT. High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response). Emerg Infect Dis. 2022;28(5):1083-1084. https://doi.org/10.3201/eid2805.220363 |
|---|---|
| AMA | De Santis GC, Calado RT. High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response). Emerging Infectious Diseases. 2022;28(5):1083-1084. doi:10.3201/eid2805.220363. |
| APA | De Santis, G. C., & Calado, R. T. (2022). High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response). Emerging Infectious Diseases, 28(5), 1083-1084. https://doi.org/10.3201/eid2805.220363. |
Volume 28, Number 3—March 2022
Addendum to Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level [PDF - 691 KB - 1 page]
| EID | Barr IG, Williams TC, Salimi V, Buchholz UJ. Addendum to Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level. Emerg Infect Dis. 2022;28(3):764. https://doi.org/10.3201/eid2803.212438 |
|---|---|
| AMA | Barr IG, Williams TC, Salimi V, et al. Addendum to Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level. Emerging Infectious Diseases. 2022;28(3):764. doi:10.3201/eid2803.212438. |
| APA | Barr, I. G., Williams, T. C., Salimi, V., & Buchholz, U. J. (2022). Addendum to Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level. Emerging Infectious Diseases, 28(3), 764. https://doi.org/10.3201/eid2803.212438. |
Volume 28, Number 2—February 2022
High Infection Attack Rate after SARS-CoV-2 Delta Surge, Chattogram, Bangladesh [PDF - 1.01 MB - 2 pages]
| EID | Hegde ST, Bhuiyan T, Akhtar M, Islam T, Hulse J, Khan Z, et al. High Infection Attack Rate after SARS-CoV-2 Delta Surge, Chattogram, Bangladesh. Emerg Infect Dis. 2022;28(2):491-492. https://doi.org/10.3201/eid2802.212417 |
|---|---|
| AMA | Hegde ST, Bhuiyan T, Akhtar M, et al. High Infection Attack Rate after SARS-CoV-2 Delta Surge, Chattogram, Bangladesh. Emerging Infectious Diseases. 2022;28(2):491-492. doi:10.3201/eid2802.212417. |
| APA | Hegde, S. T., Bhuiyan, T., Akhtar, M., Islam, T., Hulse, J., Khan, Z....Qadri, F. (2022). High Infection Attack Rate after SARS-CoV-2 Delta Surge, Chattogram, Bangladesh. Emerging Infectious Diseases, 28(2), 491-492. https://doi.org/10.3201/eid2802.212417. |
Predictors of Nonseroconversion after SARS-CoV-2 Infection [PDF - 618 KB - 2 pages]
| EID | Davido B, Jaffal K, Annane D, Lawrence C, Gault E, De P. Predictors of Nonseroconversion after SARS-CoV-2 Infection. Emerg Infect Dis. 2022;28(2):492-493. https://doi.org/10.3201/eid2802.211971 |
|---|---|
| AMA | Davido B, Jaffal K, Annane D, et al. Predictors of Nonseroconversion after SARS-CoV-2 Infection. Emerging Infectious Diseases. 2022;28(2):492-493. doi:10.3201/eid2802.211971. |
| APA | Davido, B., Jaffal, K., Annane, D., Lawrence, C., Gault, E., & De, P. (2022). Predictors of Nonseroconversion after SARS-CoV-2 Infection. Emerging Infectious Diseases, 28(2), 492-493. https://doi.org/10.3201/eid2802.211971. |
Volume 28, Number 1—January 2022
New Delhi Metallo-β-Lactamase-Producing Enterobacterales Bacteria [PDF - 653 KB - 1 page]
| EID | Yao Y, Imirzalioglu C, Falgenhauer L, Chakraborty T. New Delhi Metallo-β-Lactamase-Producing Enterobacterales Bacteria. Emerg Infect Dis. 2022;28(1):265. https://doi.org/10.3201/eid2801.212106 |
|---|---|
| AMA | Yao Y, Imirzalioglu C, Falgenhauer L, et al. New Delhi Metallo-β-Lactamase-Producing Enterobacterales Bacteria. Emerging Infectious Diseases. 2022;28(1):265. doi:10.3201/eid2801.212106. |
| APA | Yao, Y., Imirzalioglu, C., Falgenhauer, L., & Chakraborty, T. (2022). New Delhi Metallo-β-Lactamase-Producing Enterobacterales Bacteria. Emerging Infectious Diseases, 28(1), 265. https://doi.org/10.3201/eid2801.212106. |
Page created: December 03, 2021
Page updated: April 20, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
